Monica Kwari

Author PubWeight™ 15.04^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.	Lancet Oncol	2012	2.76
2	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.	Blood	2008	2.31
3	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.	Blood	2004	2.03
4	Clofarabine combinations as acute myeloid leukemia salvage therapy.	Cancer	2008	1.77
5	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.	Blood	2006	1.73
6	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.	Cancer	2013	1.71
7	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.	Cancer	2011	1.06
8	Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.	J Clin Oncol	2010	1.04
9	Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.	Br J Haematol	2014	0.79
10	Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine.	Clin J Oncol Nurs	2011	0.75